Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | EEF2K | O00418 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21963267 | 1.00 | NLRP3 (0.46) | NLRP3USP2EEF2KCYP1A2GAA | |
| SCHEMBL30162657 | 0.90 | NLRP3 (0.45) | NLRP3USP2EEF2KCYP1A2GAA | |
| SCHEMBL30162353 | 0.90 | NLRP3 (0.45) | NLRP3USP2EEF2KCYP1A2GAA | |
| SCHEMBL22020236 | 0.90 | NLRP3 (0.45) | NLRP3USP2EEF2KCYP1A2GAA | |
| SCHEMBL21963266 | 0.90 | NLRP3 (0.59) | NLRP3USP2 | |
| SCHEMBL22020581 | 0.90 | USP2 (0.42) | NLRP3USP2CYP1A2GAANPSR1 | |
| SCHEMBL30162790 | 0.90 | USP2 (0.42) | NLRP3USP2CYP1A2GAANPSR1 | |
| SCHEMBL24978484 | 0.90 | NLRP3 (0.59) | NLRP3USP2 | |
| SCHEMBL30162069 | 0.90 | USP2 (0.42) | NLRP3USP2CYP1A2GAANPSR1 | |
| SCHEMBL22020438 | 0.89 | USP2 (0.37) | NLRP3USP2CYP1A2GAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| EP-3880660-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885USP2 4117/4885EEF2K 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.